30 August 2024
Argent BioPharma Ltd.
(Argent BioPharma or the Company)
30 June 2024 Preliminary Financial Report
Argent BioPharma, an innovative multidisciplinary drug discovery company within the biopharmaceutical sector, advises that is has released its 30 June 2024, Preliminary Financial Report, an unaudited Full Year Financial Report required under the Australian Securities Exchange's Listing Rules.
A copy of which can be found at the following URL:
https://www.investi.com.au/api/announcements/rgt/ba7eeb34-10e.pdf
-Ends-
Authorised for release by the board of directors, for further information please contact:
| Argent BioPharma Roby Zomer CEO & Managing Director +61 8 6555 2950
| Argent BioPharma Rowan Harland Company Secretary +61 8 6555 2950 |
|
| |
About Argent BioPharma
Argent BioPharma Limited (the Company) (ASX: RGT; LSE: RGT; OTCQB: RGTLF) an innovative multidisciplinary drug development Company within the biopharmaceutical sector. The Company focuses on multidisciplinary methods with Nanotechnology, developing multi-target therapies for comprehensive disease management, especially concerning the Central nervous system (CNS) and Immunology treatments.
Follow us through our social media channels:
LinkedIn: Argent BioPharma
Twitter: @ArgentBioPharma
Facebook: Argent BioPharma
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.